Opaleye Management Inc., 10% Owner at Grace Therapeutics, Inc. (GRCE), bought 11,608 shares at $2.09 ($24K) on 2026-08-14, disclosed to the SEC on 2026-08-19.
Opaleye Management Inc., a holder of over 10% of Grace Therapeutics, executed the largest insider purchase in the company's history on August 14, 2026, buying 11,608 shares at $2.09. This significant accumulation by a major shareholder suggests confidence in the company's long-term prospects despite recent market volatility.
The stock is currently trading at a forward P/E of -4.62, indicating a negative earnings outlook, and has recently faced sector-wide pressure as Health Care stocks edged lower in late afternoon trading on April 23, 2026.
Insiders have been net buyers of the stock over the past year, as noted on November 1, 2025, suggesting a consistent bullish trend among company leadership; additionally, the company faces scrutiny regarding its cash burn rate, with Simply Wall St. highlighting this concern on April 4, 2026.
The stock carries a high short interest of 11.40%, which could lead to volatility if the company fails to meet growth expectations; furthermore, the company is currently unprofitable, with Simply Wall St. noting on September 23, 2025, that Grace Therapeutics needs to drive business growth carefully.
Nothing distinguishes this filing.
| Filing → |
| GRCE | BUY | 2026-10-01 | $16K | — | Filing → |
| GRCE | BUY | 2026-09-23 | $32K | — | Filing → |
| ACOG | BUY | 2026-09-16 | $1.1M | — | Filing → |